Available BioMed/ Biotech/ Pharmaceutical Products 

Available BioMed/ Biotech/ Pharmaceutical Products


HOMEOPATHIC ORAL AND GENITAL HERPES TREATMENT. Patented. Homeopathic, OTC medicine
for treating oral and genital herpes. Indicated for the relief of pain, itching, tingling, and discomfort from recurring herpes
eruptions in and around the mouth, the genitalia and other body areas, caused by dental surgery, over-exposure to sunlight, the common cold, premenstrual tension, and physical and emotional stress.  Over-the-counter so no expensive doctors visits are needed.  For patients already diagnosed with herpes,  provides a level of freedom not previously available.  Prescription drugs for herpes typicall cost about $90.00 for a months supply versus subject treatment which retails for $24.95 in its current configuration.  Estimates are that there are 42 million Americans with herpes infections with one million new cases
annually.  The Center for Disease Control has stated that since the late1970's herpes simplex-2 (HSV-2) infections have increased 30% per year (see Fleming,DT, et al, "Herpes simplex type 2 in the United States, 1976-1997", N Eng J Med 337(16)(October 16, 1997) 1105-111.) Manufactured to the standards set forth by the Homeopathic Pharmacopoeia
of the United States.  The manufacture and sale is regulated by the FDA (NDC # 63028-100-01). HSV has recently been implicated not only in Bell's Palsy but in flare-ups of Multiple Sclerosis.  May be useful against other viruses but further testing would be needed.  Currently seeking to license this product to a major pharmaceutical or consumer products company
interested in entering or already in the natural/herbal/homeopathic marketplace.  Under the Food and Drug Act, the FDA must regulate homeopathic products.  However, federal regulations EXCEMPT homeopathic products from the requirement of safety and efficacy testing.  This "loophole" makes it very inexpensive for companies to enter the marketplace. The
product has been produced, sample and photo is available (jpeg).  The product is currently being marketed in a very limited way through one small catalogue company and through small print advertising. There are no known ownership problems. #0325A
PREVENTION OF CALCIFICATION AND DEGENERATION OF BIOLOGICAL TISSUE GRAFTS FOR IMPLANTATION IN HUMANS. Patented. The main idea of this product is the development of a biological heart valve or vascular prosthetic tissue of animal origin for human use. Accumulation of calcium salt on the leaflets and tissue deterioration of presently available commercial valves cause the valve to fail.With the subject biological heart valve no medicine is necessary for healthy lifestyle. The subject technique of anti-calcification would enable the bioprosthetic valve to function for a longer period. The result of animal experiments was published in June 1997. #0262A 
COBRANIN-F. Corbravir Injection. Patented. It has destroyed both neurotoxins and hemotoxins in many known diseases, plus is a very powerful anit-viral drug for therapeutic use.Additionally there is a CIP in progress on an additional application. Diseases treated and cured with the new drug, which is formed of generic FDA-approved compounds, are Snakebite, Paralytic Shellfish Poisoning, Rheumatoid Arthritis, Herpes zoster, marine food poisonings, and Dengue Hemorrhagic Fever (DHF). Invented overseas, inventor is looking for a major pharmaceutical company in the United States that has the capability to both license and further develop this amazing drug. #0301A 
DNA MUTATION DETECTION. Patents pending. This is an enabling technology with a wide range of potential applications in detecting known mutations and scanning for unknown mutations. Available for license. #0271A 
CHIRAL SYNTHESIS. Methods for chiral synthesis utilising novel biocatalysts. A unique collection of microbial isolates demonstrating novel biocatalytic abilities. Combining the expertise of synthetic chemists and microbiologists a group has been established to develop alternative routes to commercially important chiral synthons.Available for license. #0273A 
PEPTIDE & protein engineering. A major program on the development of novel bioactive peptides, which also focuses on peptide delivery. Targeting infectious diseases, cancer and migraine.Available for license. #0274A 
DNA PROBE generation. Patent granted. Non-exclusive licenses available. #0275A 
CANCER THERAPY. Inventions for use in cancer therapy (i) Combination therapy - for improved tumour killing using approved chemotherapeutics in combination with specific “enhancers” (patent pending). (ii) Novel use of L-deprenyl to reduce collateral damage to normal cells during radio- and chemotherapy (patent pending). Available for license. #0276A 
PROBIOTICS and Novel Antimicrobial Agents --a major program in probiotics R & D has resulted in the isolation of strains with specific "probiotic" characteristics and the discovery of novel anti microbial peptides (bacteriocins). Patents filed and supporting clinical data available.Available for license. #0277A 
CELL APOPTOSIS and Cell Cycle R&D: This programme exploits unique cell lines and in-house expertise in ribozyme technology to study the mechanisms of apoptosis, and related cell death pathways (as well as how these mechanisms interact with cell cycle control pathways). There is a particular focus on apoptotic mechanisms in cancer and multiple drug resistance.Collaborative & Contract Research Opportunity. #0279C 
CHIRAL SYNTHESIS  methods utilising novel biocatalysts. A unique collection of microbial isolates demonstrating novel biocatalytic abilities. Combining the expertise of synthetic chemists and microbiologists a group has been established to develop alternative routes to commercially important chiral synthons.Collaborative & Contract Research Opportunity. #0280C 
RECEPTOR CLONING. The Receptor Cloning Unit is a dedicated resource which may be contracted by industry to clone membrane proteins, ensuring high protein expression in animal cell lines. The Unit focused initially on the human 5HT5A serotonin receptor, and has since embarked on a major programme of cloning novel members of the new P2X family of purinergic receptors.Collaborative & Contract Research Opportunity. #0281C 
cGMP Contract Manufacture. Purpose built facilities, including class 10,000 and class 100 clean rooms and a production suite available for small to medium scale culture of mammalian and insect cells. The facility is currently being expanded and is producing a human pharmaceutical product which is on the market in several countries. Collaborative & Contract Research Opportunity. #0283C 
DRUG RESISTANCE. Multiple Drug Resistance Research. Long-established expertise in study of mechanisms of drug resistance in cancer cells. The group uses a plethora of techniques to identify and characterise drug resistance mechanisms and to develop strategies for diagnosis, intervention or circumvention. Collaborative & Contract Research Opportunity. #0284C 
INFLAMMATION  and Cellular Stress Response. Cellular stress occurs as a consequence of tissue injury, inflammation, infection and autoimmune responses and represents a novel perspective on a variety of clinical conditions including rheumatoid arthritis, ulcerative colitis and cardiovascular disease. BRI has a wide ranging programme investigating IL1 mediated stress response. Collaborative & Contract Research Opportunity. #0285C 
AGING and neurobiology. Researching aging, neurodegeneration, nutrition and brain diseases and developing novel antidepressants and anticonvulsants. Collaborative & Contract Research Opportunity. #0286C 
NUTRITION. Nutraceuticals and Nutrition: A number of projects are in , including the study of dietary supplements which reduce age-related brain impairment, Obesity and development of anti-obesity treatment strategies and a major programme in probiotics and food grade anti-bacterials. Collaborative & Contract Research Opportunity. #0287C 
DIAGNOSTIC KITS. Diagnostic Kit development. Experience in developing both DNA- and Immuno-diagnostic kits for a wide range of analytes. Prototype or market-ready test systems can be developed in a range of formats. Collaborative & Contract Research Opportunity. #0290C 
LEISHMANIA AND TOXOPLASMA DRUG TARGETS. DNA polymerase a is being investigated as a suitable drug target for the design of enzyme inhibitory drugs to control Leishmaniasis and Toxoplasmosis. The research could facilitate development of new anti-parasitic drugs that are able to differentiate between host and parasite, thereby avoiding the toxicity and side-effects of conventional treatments. Offered for license. #0151A 
RECOMBINANT ELISA TEST FOR TOXOPLASMA GONDII. A serological test utilising recombinant H4 and H11 antigen gene fragments has been developed for the diagnosis of toxoplasmosis. Offered for license. #0152A 
RECOMBINANT IMMUNOTOXIN An alternative approach to targeted cytolytic therapy is to utilise a recombinant immunotoxin incoporating the peptide melittin, a component of bee venom. The expressed product specifically binds to and kills target cancer cells at nM concentrations. The immunotoxin is being further developed to increase cytotoxicity and retain specificity through manipulation of the melittin encoding portion of the recombinant gene.Offered for license. #0153A 
RECOMBINANT VACCINE FOR BOVINE NEOSPOROSIS. A recombinant vaccine is being developed for Neospora caninum, a parasite recently recognised as a major cause of abortion in cattle. Also under development is a PCR test for Neospora in tissue sections and a serological ELISA test utilising recombinant antigens. In early development stages. #0154A 
SUBUNIT MATERNAL VACCINE AGAINST COCCIDIOSIS IN CHICKENS. As the first step in development of a vaccine against coccidiosis in chickens, a team is investigating the ability of purified Eimeria maxima proteins to induce maternal immunity against other species of Eimeria. Offered for license. #0155A 
DISEASE REMEDIES, various. The opportunities below are all housed within the same pharmaceutical development company. They have a body of patents, patents applied for, surrounding this technology which collectively constitutes several hundred compounds. + Company founded to exploit new area of lipid chemistry which can control cellular function by interfering with intracellular communications.+ DISEASE PROCESSES addressed by Company products:

+ Asthma: Likely intervention in cell signaling process preventing attacks.+ Cancer: Will likely “re-control” cell growth without current side-effect profiles.+ Inflammation: Cell signaling causes inflammation; cellular management can stop.+ Psoriasis: Attacks hyperproliferation of cell growth and underlying inflammation. + Some POTENTIAL PRODUCTS for development + Wound patch: Stops internal or external bleeding fast. + Skin care products to replenish skin plasmalogens; anti-aging; UV protection.+ Promote wound healing by stimulating granulation tissue (Vulnerary Agent).+ Menthol conjugate with anti-inflammatory activity: useful in treating muscle and joint inflammation, itchy and inflamed skin, sunburn, hemorrhoids and sore throat.+ Liquefy mucous in the Respiratory tract: lung inhalant to help expectoration of mucous in chronic and acute bronchitis, asthma and cystic fibrosis; reduction of nasal congestion due to headcolds. + Vitamin E conjugate: Targeted delivery of compounds to skin, lungs and body for planned cellular intervention.+ Treatment of inflammatory bowel disease.+ Conjugate of Retin-A useful in treating acne and actinic keratosis (UV damage).+ Synthetic lipid to treat excessive cell growth and inflammation due to psoriasis. #0242A 


ALGAMMULIN. Algammulin A new vaccine adjuvant comprising gamma inulin particles containing alum. Included in adjuvant formulations as a primary adjuvant. Addition of Algammulin is known to enhance both humoral and cell-mediated immunity from both Th1 and Th2 pathways. Patents granted in major markets. #0243A 
MHC ANTIGENS. MHC Class II Binding Molecules Novel molecules capable of binding with high affinity to MHC class II molecules and inhibiting antigen MHC II interactions. Potential for treatment of anti-immune disorders, e.g. diabetes and MS. International PCT patent application. #0244A 
IMMUNO DRUG. Novel Immunosuppressive Product Castanospermine can be used as immuno-suppressant/anti-inflammatory agent. CST delays graft rejection and improves graft acceptance, is a complementary to existing anti-T cell therapies, enhances effects of cyclosporine A. Patent applications filed for Australia , Japan, USA and Europe.#0245A 
MEMBRANE / RECEPTOR. Model Membrane System Technique to study receptor interactions using a model membrane system that mimics the cell surface, particularly suited for dimerisation/oligomerisation. Provides basis for novel method to screen drugs that affect intermolecular actions. Provisional application for patent.#0246A 
SCREENING. Des Brown Collection A collection of over 3500 chemical compounds including many novel compounds available for screening, including pyrimidines, pteridines and purines. No patents.#0247A 
GAMMA INULIN. Gamma Inulin Highly specific activator of the alternative pathway of complement in vivo and in vitro. A primary adjuvant in adjuvant formulations and an immune stimulant when combined as composite particles with alum in the adjuvant Algammulin. Patent granted in major markets.#0248A 
ION CHANNEL. Ion Channels Bioassay for the rapid screening of potential therapeutic drugs for ion channel blocking activity. Provisional application for patent.#0249A 
VECTORS. A Versatile Series of Promoter Vectors A series of stable high-copy-number bacteriophage promoter vectors for overproduction of proteins in Escherichia coli. The use of these vectors in process-scale biotechnology may eliminate the need for use of antibiotics in fermentations and obviate the necessity for demonstrating the lack of antibiotic contamination in commercial endproducts. No patent.#0250A 
ANTIBIOTIC. A New Antibiotic Compounds derived from a fungal metabolite with the potential of being a new antibiotic against bacterial, parasitic and fungal infections. Provisional patent application.#0251A 
ANTI-INFLAMMATORY. Phosphosugars as Anti-inflammatory Drugs An anti-inflammatory agent with novel and subtle mode of action. Potential for inhibiting inflammatory diseases, e.g. rheumatoid arthritis, MS, ocular and skin inflammatory diseases. Patents granted on major markets.#0252A 
DNA DIAGNOSTIC. Staphylococcus Aureus Sequence A DNA based diagnostic to identify clinically significant S. aureus strains, including both methicillin-resistant and methicillin-sensitive strains. Potential target for vaccine development or rational drug design. International PCT application has been filed.#0253A 
MH DIAGNOSTIC. Diagnostic Kit for Risk of Malignant Hyperpyrexia and Cot Death A DNA based diagnostic to screen for MH (cause of anaesthetic-induced death) and cot death predisposition. No application filed yet.#0254A 
  • METHOD OF IDENTIFYING AND SHIELDING PROTEIN FUNCTIONAL SITES 001B (#0144A)
  • AUTOMATED HDL MEASUREMENT 001E (#0161A)
  • SERINE PROTEASE MUTANTS:RESISTANCE TO COGNATE INHIBITORS AND PROLONGED ACTIVITY 003B (#0162A)
  • FLUID AND NUTRIENT REPLACEMENT BEVERAGE 003C (#0163A)
  • METHODS FOR DIAGNOSIS OF T-ALL 004C (#0164A)
  • BIO-ACTIVE DERIVATIVES CONTAINING HYDROXY-DIENE SUBUNITS 008C (#0165A)
  • CELL LINES PRODUCING H. INFLUENZAE MONOCLONAL ANTIBODIES 022 (#0166A)
  • MATERIALS WITH IMPROVED BIOCOMPATIBILITY 028 (#0167A)
  • HEAT-REGULATED PROTEIN PRODUCTION IN YEAST 031 (#0168A)
  • HUMAN LDL RECEPTOR GENE 048 (#0169A)
  • REHYDRATABLE AGAROSE GELS 070 (#0170A)
  • STEROL REGULATORY ELEMENTS 077 (#0171A)
  • TREATMENT OF HYPERCALCITRIOLEMIC DISEASE 107 (#0172A)
  • ANTIPYRETIC AND ANTI-INFLAMMATORY PEPTIDES 120 (#0173A)
  • ANTIBODY PRODUCING CHICKEN CELL CLONES 143 (#0174A)
  • SULFONAMIDE DERIVATIVES THAT INHIBIT ALLERGIC REACTION 150 (#0175A)
  • SITE-SPECIFIC DOUBLE STRANDED DNA ENDONUCLEASE 163 (#0176A)
  • IRREVERSIBLE NEP (CALLA) INHIBITORS 175 (#0177A)
  • A METHOD FOR DIAGNOSIS OF GRAM-NEGATIVE SEPTICEMIA 188 (#0178A)
  • STEROID 5a-REDUCTASES 190 (#0179A)
  • MEASUREMENT OF ACETYL-COA IN NONSTEADY-STATE CONDITIONS 202 (#0180A)
  • CYTOCHROME P450 EXPRESSION IN BACTERIA 209 (#0181A)
  • A CELL LINE PRODUCING LESS HETEROGENOUS N-LINKED GLYCANS 217 (#0182A)
  • HUMAN FARNESYL PROTEIN TRANSFERASE ENZYME 218 (#0183A)
  • ANIMAL MODEL FOR CHANCROID 221 (#0184A)
  • CYTOKINE RECEPTOR CHIMERIC PROTEINS 239 (#0185A)
  • INTERLEUKIN BINDING FACTOR 262 (#0186A)
  • TRANSDOMINANT Tat MUTANTS FOR REGULATION OF HIV 263 (#0187A)
  • A CELLULAR PROTEIN INVOLVED IN HIV GENE EXPRESSION 264 (#0188A)
  • CELLULAR FACTOR DELETED IN MANY LUNG CANCERS 270 (#0189A)
  • DIPHTHERIA TOXIN RECEPTOR 285 (#0190A)
  • FUSION PEPTIDES AND PROTEINS 288 (#0191A)
  • SOLUBLE T-CELL RECEPTOR DOMAINS SECRETED IN E. COLI 293 (#0192A)
  • DIPEPTIDYL PEPTIDASE-I INHIBITORS 296 (#0193A)
  • A NEW CLONING AND VACCINATION SYSTEM 309 (#0194A)
  • CORNEAL WOUND HEALING AND PRESERVATION 311 (#0195A)
  • EXPRESSION & SECRETION OF Ig DOMAINS IN E. COLI 320 (#0196A)
  • LDL RECEPTOR GENE TRANSFER 324 (#0197A)
  • ENHANCED RECOVERY OF RECOMBINANT PROTEINS 332 (#0198A)
  • RECEPTOR-DIRECTED COVALENT CAPTURE ASSAY 333 (#0199A)
  • DETERMINATION OF INTRACELLULAR SODIUM BY NMR 343 (#0200A)
  • SRE BINDING PROTEIN AND ASSAYS 347 (#0201A)
  • ADIPOSE-SPECIFIC PROMOTER REGIONS OF P450AROM 351 (#0202A)
  • TDP-43 AND REGULATION OF HIV-1 GENE EXPRESSION 355 (#0203A)
  • PROTEASOME REGULATORS 356 (#0204A)
  • PLASMINOGEN ACTIVATOR AND TUMORICIDAL PROTEINS 373 (#0205A)
  • AUGMENTATION OF HIGH DENSITY LIPOPROTEIN 390 (#0206A)
  • COAXIAL TRACTION DETACHMENT APPARATUS AND METHOD 391 (#0207A)
  • PSORIASIS SUSCEPTIBILITY GENE 402 (#0209A)
  • INFLAMMATORY INDUCED EXPRESSION OF A RECOMBINANT GENE 406 (#0210A)
  • EXPRESSED LIBRARY IMMUNIZATION 411 (#0211A)
  • ENDOTHELIN CONVERTING ENZYME-1 414 (#0212A)
  • SPECIES SPECIFIC EGG BINDING SPERM PROTEINS 418 (#0213A)
  • METHODS AND COMPOSITIONS FOR A NOVEL CYTOKINE 427 (#0214A)
  • ASSAY FOR NEUROFIBROMIN INHIBITORS 446 (#0215A)
  • MUTANT MAMMALIAN ADENYLYL CYCLASE 450 (#0216A)
  • ENDOTHELIN CONVERTING ENZYME-2 472 (#0217A)
  • RECOMBINANT PRODUCTION OF IMMUNOGLOBULIN-LIKEDOMAINS IN PROKARYOTIC CELLS 483 (#0218A)
  • DECTINS 1 & 2: ELUCIDATION OF DENDRITIC CELL-DEPENDENT T-CELL ACTIVATION 493 (#0219A)
  • INDUCIBLE APOPTOSIS 503 (#0220A)
  • PASSIVE IMMUNITY:RECOMBINANT HUMAN IGA-J CHAIN DIMER 505 (#0221A)
  • REGULATING VIRAL GENE EXPRESSION 1029 (#0222A)
  • C. ELEGANS IVERMECTIN RECEPTOR SUBUNIT 1180 (#0223A)
  • NOVEL OXY-STEROL LIGANDS FOR THE LXRRECEPTOR AND USES THEREOF 1184 (#0224A)
  • MERMADE: OLIGO-SYNTHESIZER 1227 (#0225A)
  • METHIONINE DEPLETION IN PLASMA AND SOLID TUMORS: 1237 (#0226A)


  • http://www.thehooktek.com <==Click here to go to The Hook's Main Page.

    Back Page<==Click here to go back to categories of the HOOK's New Products Available.

    info@thehooktek.com <==Click here if you have an interest in any of the above innovations, or if you wish to list your own invention here for FREE.

    All transations are negotiated or brokered with a performance fee or equity position paid by the licensor or client at the time of closing.

    Page last updated 4/6/99